A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19
Brief description of study
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
Clinical Study Identifier: s20-01219
ClinicalTrials.gov Identifier: NCT04516746
Principal Investigator:
Mark J. Mulligan.
Other Investigators:
Alan Jacobson,
Jennifer Lee Dong,
Jennifer Nierman Knishinsky,
Diane H Johnson,
Kelly Minus,
Stephanie Sterling,
Rebecca Boas,
Steven E Carsons,
Nicole A. Szabo,
Stephanie Lynn Mawhirt,
Melinda Katz,
Melanie R Jay,
Asif Noor,
Kiana D Piedrahita,
Rebecca Pellett Madan,
Adam Schwartz,
Angelica Cifuentes Kottkamp,
Sabrina E Felson,
Lois Anne Katz,
Dinuli Hashangani Delpachitra,
Reny Jose,
Ellie R. Carmody,
Bo Shopsin,
Grace Lioue,
Claudia Patricia De La Matta Rodriguez,
Janette Hernandez Torres,
Sigridh A Munoz-Gomez,
Sajumon K Joseph,
Ramin Herati,
Adina Claudia Musta,
Urmee Saha,
Daniel Sartori,
Martin Backer,
Robert James Ulrich,
Kevin Douglas Zhang,
Scarlett I Metellus,
Vanessa N Raabe,
Reza P Parungao,
Mary Christine Olson,
Alexander Mcmeeking,
Diana Badillo,
Jose O. Aleman,
Elisabeth J. Cohen,
Tamia Davis,
Lalitha Parameswaran,
Benjamin J Eckhardt,
Janine M. Sullivan,
Erwin Christian Wang,
Jay Pendse,
Purvi S. Parikh.
If you are registered as a volunteer, please login to the dashboard to send referrals.
